ダウンロード数: 200
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
66_10_357.pdf | 948.25 kB | Adobe PDF | 見る/開く |
タイトル: | 治療中断後に腫瘍縮小が続きCRとなった右精巣腫瘍・多発転移の1例 |
その他のタイトル: | A Case of Testicular Tumor with Multiple Metastasis Leading to Complete Response after Treatment Interruption |
著者: | 勝又, 有記 佐藤, 真彦 大竹, 航太郎 千葉, 大豪 今野, 将人 竹本, 淳 星, 宣次 沼畑, 健司 |
著者名の別形: | Katsumata, Yuki Satou, Masahiko Otake, Kotaro Chiba, Daigo Konno, Masato Takemoto, Jun Hoshi, Senji Numahata, Kenji |
キーワード: | Testicular tumor Treatment interruption Complete response Residual tumor |
発行日: | 31-Oct-2020 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 66 |
号: | 10 |
開始ページ: | 357 |
終了ページ: | 362 |
抄録: | A 39-year-old man experiencing cranial nerve symptoms was referred to our neurosurgery department after a brain tumor was detected on computed tomography (CT) scans at a local hospital. Due to convulsive symptoms, the patient was admitted to our hospital for detailed examination. The patient was diagnosed with right testicular tumor, multiple brain metastases, multiple lung metastases and right kidney metastases, and was transferred to our urology department. Since the testicular tumor was staged as IIIC and identified as poor prognosis by the International Germ Cell Consensus classification (IGCCC), Bleomycin Etoposide Cisplatin (BEP) chemotherapy was initiated prior to surgery. A right high orchiectomy was performed after two courses of BEP chemotherapy. Histopathology revealed mixed germ cell tumors (seminoma and/or embryonal carcinoma+teratoma) along with the following results : ly (−) ; Intratubular Malignant Germ Cells (ITMGC) (+, viable) ; tunica albuginea invasion (−) ; spermatic cord invasion (−) ; tumor size (73× 50×45 mm). Two additional courses of BEP chemotherapy and two courses of Paclitaxel Ifomaide Cisplatin(TIP) chemotherapy were performed successively. The CT revealed metastatic lesions shrinking steadily but the metastatic foci still remained. Since tumor markers were not negative, continuous chemotherapy was considered. However, strong side effects were expected, and treatment was discontinued. Since then, the tumors continued to shrink, and the tumor markers became negative. Currently, the patient maintains complete response and is being followed-up. |
著作権等: | 許諾条件により本文は2021/11/01に公開 |
DOI: | 10.14989/ActaUrolJap_66_10_357 |
URI: | http://hdl.handle.net/2433/259373 |
PubMed ID: | 33271650 |
出現コレクション: | Vol.66 No.10 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。